• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: COOK IRELAND LTD ZILVER FLEX 35 VASCULAR SELF-EXPANDING STENT; NIO STENT, ILIAC

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

COOK IRELAND LTD ZILVER FLEX 35 VASCULAR SELF-EXPANDING STENT; NIO STENT, ILIAC Back to Search Results
Catalog Number UNKNOWN
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Thrombosis/Thrombus (4440)
Event Date 08/22/2022
Event Type  Injury  
Event Description
Liu 2022 midterm outcomes of endovascular therapy for tasc ii d femoropopliteal lesions with critical limb ischemia: a retrospective analysis.Fifty seven limbs of 54 patients with cli due to tasc ii d femoropopliteal lesions who underwent evt at (b)(6) hospital were retrospectively analysed in a single-centre, observational study.The patient characteristics, endovascular procedural details, freedom from target lesion revascularization (tlr), patency rates, ulcer healing rate, and limb salvage rate were accessed.57 limbs of 54 patients referred for evt of tasc ii d femoropopliteal lesions with cli were included in this observational, single-arm, single-institution, prospective study.Male, n (%) 41 (75.9).Age (years, mean ± sd) 68.2 ± 8.2.Access to the target lesion was determined using a 6 f 45- cmelong sheath (fortress, biotronik, dresden, germany), crossing over the aortic bifurcation, or using a 6 f 16-cmelong sheath (radifocus, terumo corporation, hanoi, vietnam) via an antegrade approach.After sheath placement, unfractionated 100 iu/kg heparin was administered by injection.A 0.035-inch hydrophilic guidewire (150 cm, radifocus, terumo corporation) crossed through the culprit lesions.The target vessel was first opened in the true lumen and a subintimal technique was used if this failed.To reduce damage, a balloon with a diameter 1 mm narrower than the target vessel was chosen.Predilation with small balloon catheter was performed for 2 min to limit the risk of dissection.Using a stent sizing selected to a 1:1 ratio to the normal artery segment diameter and extending at least 10 mm past the lesion proximally and distally.Adjacent stents were overlapped by 1 cm maximum.A radiopaque ruler was used to measure the length of the stented segment.Four types of nitinol self-expanding stents were implanted: protege everflex (ev3, plymouth, minnesota), aston pulsar (biotronik, berlin, german), lifestent (bard peripheral vascular, tempe, arizona), and zilver flex (cook, limerick, ireland).The routinely post dilated balloon after stenting was performed within the stented segment.In case of a percutaneous approach, groin closure was accomplished by manual compression or by using a vascular closure device (2-mm perclose proglide, abbott vascular, diegem, belgium).The complaint captures thrombosis requiring medication.
 
Manufacturer Narrative
Pma 510k #p050017/s006.Investigation is still pending, a follow up mdr will be submitted to include the investigation conclusions.
 
Manufacturer Narrative
Pma 510k #p050017/s006.Device evaluation: the zilver flex devices of lot numbers and rpns unknown, involved in this complaint, were implanted into the patients and were not available for evaluation.With the information provided, a document-based investigation was conducted.This complaint was raised from literature paper liu 2022 midterm outcomes of endovascular therapy for tasc ii d femoropopliteal lesions with critical limb ischemia: a retrospective analysis.It is related to (b)(4) and captures 01 occurrence of thrombosis requiring medication.The device evaluation could not be completed as the devices or photographic evidence of the devices were not returned for evaluation.With the information provided, a document-based investigation was conducted.Manufacturing records review: prior to distribution all zilver flex devices are subjected to a visual inspection and functional inspection to ensure device integrity.Manufacturing records review could not be completed as the lot number is unknown.Instructions for use and label: it should be noted that thrombosis is listed as a potential adverse event of this device in the technical content form for ifu0058.There is no evidence to suggest the user did not follow the instructions for use image review : an image was not returned for evaluation.Root cause analysis: a definitive root cause could not be determined from the available information.It is possible that patient pre-existing conditions caused or contributed to the event of thrombosis.From the information available, it is known that the patient had peripheral artery disease.Risk factors for thrombosis include smoking, high blood pressure and high cholesterol.It is known from the article that hypertension and hypercholesterolemia were present in almost 80% of the patients in the study and approximately half of the patients were past or current smokers.There is no evidence to suggest the device malfunctioned or deteriorated in performance characteristics during the study.As previously mentioned, thrombosis is listed as a potential adverse event in the technical content form for ifu0058.Confirmation of complaint: complaint is confirmed based on customer testimony and/or rep testimony.Summary of investigation: according to the initial reporter, this complaint was raised from literature article fifty seven limbs of 54 patients with cli due to tasc ii d femoropopliteal lesions who underwent evt at the first hospital of hebei medical university were retrospectively analysed in a single-centre, observational study.The patient characteristics, endovascular procedural details, freedom from target lesion revascularization (tlr), patency rates, ulcer healing rate, and limb salvage rate were accessed.The complaint captures 01 occurrence of thrombosis requiring medication confirmed quantity of 01 device, confirmed used.According to the initial reporter, there was 01 occurrence of thrombosis which was treated successfully with thrombolytic therapy.Investigation findings conclude possible root causes could be attributed to the patients pre existing conditions.Complaints of this nature will continue to be monitored for potential emerging trends.
 
Event Description
Supplemental report being submitted due to the completion of the investigation on 03-jan-2024.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ZILVER FLEX 35 VASCULAR SELF-EXPANDING STENT
Type of Device
NIO STENT, ILIAC
Manufacturer (Section D)
COOK IRELAND LTD
o halloran road
limerick
Manufacturer (Section G)
COOK IRELAND LTD
o halloran road
national technology park
limerick
Manufacturer Contact
sinead o'leary
o halloran road
national technology park
limerick 
MDR Report Key17245338
MDR Text Key318285643
Report Number3001845648-2023-00524
Device Sequence Number1
Product Code NIO
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 01/03/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/03/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNKNOWN
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Distributor Facility Aware Date08/22/2022
Event Location Hospital
Date Manufacturer Received05/31/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age69 YR
Patient SexMale
-
-